Switching from biology treatment of AD to a JAK inhibitor resulted in improved efficacy

In this MEDtalk Andrew Blauvelt, dermatologist, presents the results of switching from dupilumab to upadacitinib in moderate to severe atopic dermatitis. This resulted in improved efficacy with higher rates of skin clearance and itch improvement when compared to week 24 response rates.